Author

Muthukumaran Natarajan

OpenAlex ID: A5104884564

766-P: Safety and Tolerability of Once-Weekly GL0034 (Utreglutide) in Healthy Individuals—A Multiple Ascending Dose Study

2023 · RAJAMANNAR THENNATI, VINOD S. BURADE, et al. · Diabetes · 2

759-P: Effects of Once-Weekly Utreglutide (GL0034) in Individuals with Overweight and Obesity on Lipid Metabolism—A 10-Week Exploratory Proof-of-Concept Study

2025 · RAJAMANNAR THENNATI, VINOD S. BURADE, et al. · Diabetes · 1

765-P: A Single Ascending Dose Study of the Novel GLP-1 Receptor Agonist GL0034 (Utreglutide) in Obese Individuals without Diabetes

2023 · RAJAMANNAR THENNATI, VINOD S. BURADE, et al. · Diabetes · 1

2833-LB: Utreglutide (GL0034) Shows Comparable Tolerability and Efficacy with Different Dose Escalation Regimens in Overweight and Obese Adults with Type 2 Diabetes (T2DM)

2026 · RAJAMANNAR THENNATI, GRIT ANDERSEN, et al. · Diabetes

1700-P: Durable Cardiometabolic Effects of Utreglutide in Metabolic Dysfunction–Associated Steatotic Liver Disease Patients with Nondiabetic and Prediabetic Status

2026 · RAJAMANNAR THENNATI, VINOD BURADE, et al. · Diabetes

116-OR: GL0034 (Utreglutide), a Novel GLP-1RA, Increases Liver FGF-21 and Demonstrates Significant Efficacy on Weight Loss, HbA1c, and Triglycerides in db/db Mice

2024 · RAJAMANNAR THENNATI, VINOD S. BURADE, et al. · Diabetes

121-OR: Safety, Tolerability, and Metabolic Effects of Once-Weekly GL0034 (Utreglutide) in Individuals with Obesity—A Multiple Ascending Dose Study

2024 · RAJAMANNAR THENNATI, VINOD S. BURADE, et al. · Diabetes

Works count: 7

Citation count: 4

H-index: 1

I10-index: